Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
17 Aug 2017 Liquid Biopsy Screening for Nasopharyngeal Carcinoma Epidemiology/Etiology/Cancer Prevention - Head and neck cancers
16 Aug 2017 EU Commission Launches Public Consultation on Health and Care in the Digital Single Market Bioethics, legal and economic issues
15 Aug 2017 FDA Grants Regular Approval to Enasidenib for the Treatment of Relapsed or Refractory AML Personalised medicine - Haematologic malignancies - Anticancer agents & Biologic therapy
14 Aug 2017 The EU needs a more coherent research funding landscape Bioethics, legal and economic issues
11 Aug 2017 FDA Grants Nivolumab Accelerated Approval for MSI-H or dMMR Colorectal Cancer Cancer in Special Situations - Gastrointestinal cancers - Cancer Immunology and Immunotherapy
10 Aug 2017 FDA Accepts Applications for Nivolumab Four Week Dosing Schedule Across All Approved Indications Cancer Immunology and Immunotherapy
08 Aug 2017 EMA Recommends Refusal of the Marketing Authorisation for Etirinotecan Pegol Breast cancer - Anticancer agents & Biologic therapy
08 Aug 2017 Response Evaluation and Biomarker Development in Onco-Immunology
07 Aug 2017 EMA Adopts a New Indication for Obinutuzumab Haematologic malignancies - Anticancer agents & Biologic therapy
04 Aug 2017 EMA Recommends Granting a Marketing Authorisation for Telotristat Ethyl Endocrine and neuroendocrine tumours
03 Aug 2017 EMA Recommends Granting a Marketing Authorisation for Avelumab Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
02 Aug 2017 Immune Contexture of Cancer
31 Jul 2017 FDA Expands Approval of Ipilimumab to Include Paediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma Cancer in Special Situations - Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
28 Jul 2017 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide Endocrine and neuroendocrine tumours
27 Jul 2017 EMA Recommends Granting a Marketing Authorisation for Midostaurin Haematologic malignancies - Anticancer agents & Biologic therapy